Currently, it is also recommended in patients with triple-negative cancer (TNBC), with the presence of HER-2 + receptors (Luminal B HER2-positive and HER-positive non-luminal subtype), and in cases of luminal B HER2-negative tumors with low expression of hormone receptors, with high grade of malignancy (G3) in patients at an early age (≤ 35 years) in the second or third stage of cancer [2–4]. The gene discussed is ERBB2; the disease is cancer.